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Abstract
Introduction: Gene amplification of CCND1 is observed in a subgroup of breast cancers with poor prognosis,
whereas overexpression of the protein cyclin D1 has been linked to both worse and better clinical outcome.
CCND1 amplification and protein overexpression have also been associated with resistance to treatment with
tamoxifen or even to a potentially detrimental effect of tamoxifen.
Methods: To clarify these challenging and partly contrasting treatment predictive and prognostic links for cyclin D1
we analysed a large cohort of postmenopausal breast cancer patients randomised to receive either adjuvant
anastrozole or tamoxifen, as part of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. The CCND1
amplification status and protein expression of cyclin D1 were assessed by chromogenic in situ hybridisation and
immunohistochemistry, respectively, in 1,155 postmenopausal, oestrogen-receptor-positive breast cancer patients
included in the TransATAC substudy.
Results: Amplification of CCND1 was observed in 8.7% of the tumours and was associated with increased risk of
disease recurrence (hazard ratio = 1.61; 95% confidence interval, 1.08 to 2.41) after adjustment for other
clinicopathological parameters. In contrast, nuclear expression of cyclin D1 protein was associated with decreased
recurrence rate (hazard ratio = 0.6; 95% confidence interval, 0.39 to 0.92). The intensity of nuclear or cytoplasmic
expression was not of prognostic value. There was no significant interaction between cyclin D1 status and treatment
efficacy, ruling out any major detrimental effect of tamoxifen in CCND1-amplified postmenopausal breast cancer.
Conclusions: In summary, CCND1 amplification and low nuclear expression of cyclin D1 predicted poor clinical
outcome in postmenopausal breast cancer patients treated with either anastrozole or tamoxifen.
Trial Registration: Current Controlled Trials ISRCTN18233230.
Introduction
Hormone dependence is a fundamental hallmark of the
majority of breast cancers, and tumour growth can be
inhibited either by deprivation of circulating oestrogens
or by antagonising the effect of these hormones on their
receptors [1]. The selective oestrogen receptor (ER)
modulator tamoxifen has long been the most commonly
used adjuvant therapy for patients with advanced hor-
mone-sensitive breast cancer [2]. In recent years, how-
ever, aromatase inhibitors have become an alternative
treatment option for postmenopausal women with breast
cancer. An aromatase inhibitor acts by interfering with
the enzyme that converts androgens to oestrogen, and
reduces tumour and systemic oestrogen concentration
[3]. The third-generation selective aromatase inhibitor
anastrozole (Arimidex) reduces serum oestradiol to
nanomolar concentrations [4]. The Arimidex, Tamoxifen,
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Alone or in Combination (ATAC) trial was designed to
compare the efficacy of anastrozole alone or in combina-
tion with the established adjuvant treatment, tamoxifen
for 5 years, as adjuvant treatment for postmenopausal
women with operable breast cancer [5]. The study
demonstrated that the efficacy of anastrozole was higher
compared with tamoxifen alone, and also superior to the
combination of both agents [5,6]. After a median follow-
up of 10 years, 5 years after completion of treatment, the
significant advantage for anastrozole over tamoxifen as
initial adjuvant therapy for postmenopausal, ER-positive
breast cancer patients was confirmed [7].
In breast cancer, genetic alterations such as amplifica-
tions and deletions occur within the tumour at high fre-
quencies, and a number of these alterations are closely
related to poor clinical outcome. One such region of
amplification is 11q13, harbouring the cyclin D1 gene
CCND1 [8-10]. Cyclin D1 plays a crucial role as a cell
cycle regulator, promoting progression through the G1-S
phase, following complex formation with CDK4/6 and
phosphorylation of the retinoblastoma protein [11].
Various studies have described the oncogenic capacity of
cyclin D1 in vitro, and overexpression in vivo results in
tumour formation [12-14]. Overexpression of cyclin D1 is
observed in approximately 50% of breast cancers [15,16],
and cyclin D1 is one of the most commonly overex-
pressed proteins in this form of cancer. A number of stu-
dies report cyclin D1 overexpression to be a predictor of
worse prognosis [17,18], while others have found an asso-
ciation with an ER-positive phenotype and a better clini-
cal outcome [19-23]. In about 15% of all primary breast
cancers, overexpression is due to amplification of the
corresponding gene CCND1 [15,24,25], and this specific
amplification has been linked to poor prognosis [23,26].
Despite the presence of ERa, approximately 50% of
breast cancers develop resistance to hormonal treatment,
a major clinical limitation of breast cancer therapy
[27,28]. The mechanisms behind this phenomenon have
been extensively studied, and imply a complex signalling
network governing ER function and interaction with var-
ious co-regulators [29-32]. Cyclin D1 is one such co-fac-
tor, known to interact with ERa and, independently of
oestrogen, activate the receptor and potentially modify
oestrogen/anti-oestrogen responses [33,34]. Overexpres-
sion of cyclin D1 has been reported to result in a confor-
mational change in ERa that induces receptor activation
in the presence of the novel selective ER modulator
arzoxifene, which in turn promotes growth of MCF-7
cells - indicating a change from antagonist to agonist
[28]. This study also suggests that different mechanisms
are required to confer resistance depending on the speci-
fic anti-oestrogen administered, and that changes in the
conformation of ERa play a crucial role in anti-hormonal
insensitivity. A similar study demonstrated that
overexpression of cyclin D1 reversed the growth inhibi-
tory effect of tamoxifen in two ER-positive breast cancer
cell lines [35]. In line with these experimental findings
we have previously observed that cyclin D1 overexpres-
sion was associated with tamoxifen resistance in preme-
nopausal and postmenopausal breast cancer [21,36].
Worryingly, amplification of CCND1 was further linked
to a potentially detrimental effect of tamoxifen in preme-
nopausal breast cancer patients, when compared with
randomised control patients not receiving any adjuvant
therapy [36].
The aim of our study was to characterise the associa-
tion between CCND1 amplification and cyclin D1 pro-
tein expression and breast cancer recurrence in a large
randomised cohort of postmenopausal patients with ER-
positive breast cancer treated with endocrine therapy. In
addition, we aimed to assess whether there was a signifi-
cant difference in response to anastrozole versus tamox-
ifen according to cyclin D1 gene and protein status, and
thereby to address any potentially unfavourable effects




The ATAC trial originally evaluated the efficacy and
safety of 5 years of anastrozole, tamoxifen, or the com-
bination of both treatments in postmenopausal patients
presenting with localised breast cancer [7]. For the
TransATAC protocol, formalin-fixed, paraffin-embedded
blocks of the primary tumour were collected from as
many hormone-receptor-positive patients as possible,
from the monotherapy trial arms [37]. The endpoint for
the analyses was any breast cancer recurrence and the
median follow-up time was 10 years. The original study
was performed according to the Declaration of Helsinki
after approval by an institutional review board and
ethics committee, and informed consent was obtained
from all patients enrolled in the study.
Immunohistochemistry
Nine tissue microarrays (TMAs) were used, each origin-
ally including from 165 to 200 tumour tissue samples
from the patients included in the TransATAC study.
This set of TMAs had one tissue core for each patient:
a sample set was analysed for cyclin D1 protein expres-
sion and a set was analysed for CCND1 copy number.
For detailed description of the TMA assembly we refer
to our previously published study [37]. The TMA slides
were deparaffinised, rehydrated and microwave-treated
in target retrieval solution pH 9.9 (Dako, Glostrup, Den-
mark), and were processed in an automated immunos-
tainer (Techmate 500; Dako, Copenhagen, Denmark)
using the Envision software (Dako, Glostrup, Denmark).
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The antibody employed was a mouse monoclonal anti-
body reactive against human cyclin D1 (1:100, clone
DSC-6; Dako, Glostrup, Denmark).
Staining of cyclin D1 was assessed as cytoplasmic stain-
ing intensity (0 to 2) as well as nuclear staining intensity (0
to 3) and fraction-positive nuclei (0, < 1%, 1 to 9%, 10 to
32%, 33 to 67% and > 67%) according to the Allred Score
[38]. Evaluation was performed by two independent obser-
vers (one a pathologist), with the pathologist’s score super-
seding the other observer’s at consolidation. Conflicting
observations were low (< 5%) for all evaluations made. All
immunohistochemical evaluations were performed with-
out knowledge of tumour characteristics. In cases of no
evaluation, the tumour cores were either nonrepresenta-
tive (that is, no invasive tumour cells) or were missing.
This study was carried out and is reported according to
REMARK guidelines [39].
Chromogenic in situ hybridisation
Chromogenic in situ hybridisation (CISH) was performed
according to the Zymed SPoT-Light Cyclin D1 Probe pro-
tocol suited for CISH [40] using the SPoT-Light Cyclin D1
Amplification Probe (Zymed Laboratories, Invitrogen
Immunodetection, San Francisco, CA, USA). Pretreatment
procedures included heating and enzyme digestion to opti-
mise the CISH performance. Nonamplified cases were
classified as 0, cases with up to 8 copies classified as 1 and
> 8 copies classified as 2. In statistical analyses, classifica-
tions 1 and 2 were both included in the subgroup defined
as amplified.
Statistical analyses
The primary endpoint for the analyses was time to recur-
rence (TTR), also known as the recurrence-free interval.
TTR was defined as the time from randomisation to first
locoregional recurrence, distant recurrence or contralat-
eral disease. Statistical analyses were performed according
to a prespecified statistical analysis plan approved by the
ATAC Steering Committee. Cox proportional hazards
regression models were fitted to TTR, and hazard ratios
(HRs) and associated 95% confidence intervals (CIs) were
estimated. The statistical tests employed for correlations
between cyclin D1 variables and clinicopathological para-
meters were the Armitage’s trend test, the Wilcoxon test,
the Goodman’s test and the Cuzick test [41]. Multiple
hypothesis testing was not corrected for, thus marginal P
values should be interpreted with caution. The contribu-
tion of cyclin D1 protein expression was analysed by the
change in likelihood ratio chi-squared test (one degree of
freedom) univariately and multivariately, in addition to a
model with tumour size, nodal status, grade (central) and
Ki67 expression, for all patients and nonamplified patients.
All hypothesis tests were conducted at the two-sided
P = 0.05 level. For detailed description of statistical ana-
lyses, we refer to a previous report [42].
Results
Distribution of CCND1 amplification status and cyclin D1
protein staining categories
In the ATAC trial, 5,880 hormone-receptor-positive
breast cancer patients were randomly assigned to receive
the monotherapy anastrozole or tamoxifen. For the
TransATAC protocol, 1,868 patients from the monother-
apy arms were initially included. In the present study,
627 patients were not assessable for CCND1 amplifica-
tion status due to missing or damaged tissue cores, and
86 patients were excluded as they did not meet the study
criteria of being ER-positive, leaving 1,155 patients asses-
sable for CCND1 amplification status. Out of the patients
with known amplification status, 1,054 (91.3%) exhibited
nonamplified tumours and 101 (8.7%) were amplified
(Figure 1a). High cyclin D1 cytoplasmic intensity was
observed in 380 tumours (32.9%), high nuclear cyclin D1
intensity in 278 tumours (24.1%), and 190 tumours
(16.5%) had > 67% nuclear fraction positivity as detailed
in Additional file 1. CCND1 gene amplification was asso-
ciated with a higher expression of nuclear cyclin D1 (P <
0.001) as well as a higher fraction of positive nuclei (P <
0.001), but was not significantly correlated to the amount
of cytoplasmic protein (P = 0.063) (Table 1 and Figure
1b). Furthermore, positive correlations were observed
between nuclear and cytoplasmic components of cyclin
D1 protein expression.
CCND1 gene amplification and patient prognosis
Initially we studied the association between CCND1
amplification status and TTR. Survival plots showed
that patients exhibiting CCND1-amplified tumours had
an increased risk of recurrence compared with patients
showing nonamplified tumours (HR = 2.04; 95% CI,
1.37 to 3.03; c1
2 = 10.51; P < 0.001, univariate) (Figure
2a). Even when adjusting for the effects of tumour size,
nodal status, grade (central) and Ki67 expression, ampli-
fication of CCND1 was significantly associated with an
increased risk of recurrence (HR = 1.61; 95% CI, 1.08 to
2.41; P = 0.03) (Table 2).
Cyclin D1 protein expression and patient prognosis
We next investigated how cyclin D1 protein localisation
and expression was related to TTR. There was no signif-
icant difference in TTR with relation to cytoplasmic
cyclin D1 (Figure 2b) or cyclin D1 nuclear intensity (Fig-
ure 2c and Table 2). Surprisingly, a greater fraction of
cyclin D1-positive nuclei was associated with longer
TTR (HR = 0.60; 95% CI, 0.39 to 0.92; P = 0.03) when
adjusted for the effects of tumour size, nodal status,
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grade and Ki67 expression (Figures 2d, 3b and Table 2).
Also, when subcategorising patients into high versus
lower subgroups of cytoplasmic cyclin D1 there was a
trend towards a significant difference in TTR (P =
0.055; univariate, HR = 0.71; 95% CI, 0.51 to 0.98; P =
0.039) (Figure 3a and Table 2). When focusing on the
non-amplified breast cancer samples, high cytoplasmic
cyclin D1 protein expression was indeed associated with
a better outcome (P = 0.005) (Figure 3c and Table 2).
The data further indicated that the lowest fraction of
cyclin D1-positive nuclei (< 1%) was associated with
shorter TTR compared with subgroups of higher per-
centage positive nuclei, as illustrated in Figure 3b, d.
Unfortunately, the number of CCND1-amplified cases
was too low to analyse survival according to nuclear
protein expression; that is, this subgroup contained no
cases exhibiting a nuclear protein expression < 1%.
Interactions of cyclin D1 and treatment, nodal status and
Ki67
Based on previous reports indicating that amplification of
the CCND1 gene and cyclin D1 overexpression might be
associated with tamoxifen resistance or detrimental
effects, we wanted to elucidate whether this could be
further clarified in the patient cohort of the present
study. The subgroup of patients treated with tamoxifen
included 571 cases, and the anastrozole-treated subgroup
included 584 patients. For CCND1 amplification status
there was no significant difference in TTR between ana-
strozole-treated and tamoxifen-treated patients (Figure
4a). Moreover, for nonamplified cases there was no dif-
ference according to nodal status or Ki67 levels between
the treatment arms. For cytoplasmic cyclin D1 expression
there was an association in TTR according to amplifica-
tion status (HR = 2.8; 95% CI, 1.2 to 6.4 for the interac-
tion) (Figure 4b). In nonamplified breast cancers,
however, no significant difference in TTR was observed
for treatment (HR = 1.8; 95% CI, 0.8 to 3.9 for the inter-
action), nodal status (HR = 1.5; 95% CI, 0.7 to 3.2) or
Ki67 levels (HR = 1.3; 95% CI, 0.6 to 3.0) (Figure 4b).
Finally, for the nuclear fraction we observed an associa-
tion in Ki67 levels for TTR (HR = 3.5; 95% CI, 1.0 to 12.3
for the interaction) (Figure 4c).
Cyclin D1, CCND1 and clinicopathological data
The CCND1 amplification status was positively corre-
lated to tumour grade (P < 0.001) and proliferation
(defined as Ki67 expression) (P < 0.001), but not to
nodal status or tumour size (Table 1). Cytoplasmic
cyclin D1 expression was inversely correlated to tumour
size (all patients; P = 0.01) and nodal status (P = 0.031),
and was positively correlated to proliferation (P =
0.021). Both nuclear staining intensity of cyclin D1 and
fraction-positive nuclei were associated with higher
Figure 1 Chromogenic in situ hybridisation and immunohistochemical staining of breast cancer samples. (a) Two copies of the CCND1
gene represents nonamplified patients (i). A copy number of 3 to 8 copies was considered a gain (ii). Amplified tumours often exhibit a very
high number of CCND1 gene copies (iii). (b) Low cytoplasmic staining without nuclear cyclin D1 expression (i). Low cyclin D1 expression in
cytoplasm and low fraction-positive nuclei displaying weak staining intensity of most nuclei (ii). Intermediate cytoplasmic expression and
fraction-positive nuclei, with nuclei showing moderate staining intensity (iii). High cytoplasmic and nuclear expression of cyclin D1, with nuclear
fraction > 67% (iv).
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Table 1 Associations between CCND1 amplification status, cyclin D1 protein expression and clinicopathological variables in all patients
All patients Cyclin D1 cytoplasmic intensity
(negative/low, intermediate,
high)
Cyclin D1 nuclear intensity
(negative/low, intermediate,
high)
Cyclin D1 nuclear fraction (< 1%,1












Nonamplified 12%, 52%, 36% 40%, 36%, 24% 10%, 24%, 27%, 24%, 15% 23%, 61%, 16% 18.0 70%, 23%, 7% 4.0
Amplified 6%, 48%, 46% 9%, 35%, 56% 0%, 6%, 18%, 32%, 44% 9%, 62%, 29% 19.0 64%, 26%, 10% 7.5








Cyclin D1 cytoplasmic intensity
Negative/low 74%, 16%, 10% 23%, 33%, 26%, 11%, 4% 26%, 59%, 15% 17.5 68%, 24%, 8% 3.2
Intermediate 40%, 36%, 24% 10%, 24%, 27%, 25%, 14% 17%, 63%, 20% 19.0 64%, 34%, 2% 4.6
High 20%, 43%, 37% 3%, 16%, 25%, 28%, 28% 23%, 61%, 16% 17.0 74%, 20%, 6% 5.6








Cyclin D1 nuclear intensity
Negative/low 23%, 33%, 26%, 11%, 4% 24%, 62%, 14% 18.0 67%, 25%, 8% 2.9
Intermediate 1%, 12%, 41%, 36%, 10% 18%, 65%, 17% 18.0 68%, 25%, 7% 4.8
High 0%, 1%, 7%, 37%, 55% 17%, 59%, 24% 17.5 71%, 22%, 7% 6.3








Cyclin D1 nuclear fraction
< 1% 18%, 68%, 14% 20.0 2%, 29%, 9% 2.8
1 to 9% 23%, 62%, 15% 18.0 68%, 25%, 7% 2.7
10 to 32% 24%, 59%, 17% 18.0 71%, 25%, 4% 4.4
33 to 67% 20%, 59%, 21% 18.0 70%, 21%, 9% 4.9
> 67% 12%, 68%, 20% 16.0 68%, 24%, 8% 5.9





Cuzick trend (P =
0.694)
Spearman r
= 0.22 (P <
0.001













grade (P < 0.001 and P = 0.005 respectively) and higher
proliferation rate (both P < 0.001).
Cyclin D1, proliferation and time to recurrence
Ki67 expression is a common marker used to analyse the
proliferation rate in tumour samples, and high prolifera-
tion is linked to a more aggressive tumour phenotype. Sur-
prisingly, despite a positive correlation between nuclear
cyclin D1 expression and Ki67 expression (Table 1 and
Figure 5a), high expression of nuclear cyclin D1 was asso-
ciated with an improved TTR compared with low expres-
sion. To further illustrate how a combined proliferation
and cyclin D1 assessment would be linked to TTR we sub-
divided patients according to Ki67 expression and nuclear
cyclin D1 status. Patients with tumours exhibiting low
Ki67 expression in association with 1 to 100% cyclin D1-
positive nuclei (high) were associated with a considerably
lower risk of recurrence (P < 0.001) (Figure 5b) compared
Figure 2 Kaplan-Meier plots of recurrence risk over time in all patients. (a) Risk of recurrence was increased for patients exhibiting CCND1-
amplified breast cancers compared with nonamplified. (b), (c) No significant difference was observed between varying intensities of cytoplasmic
or nuclear cyclin D1. (d) Patients showing a nuclear fraction of cyclin D1 lower than 1% had an increased risk of recurrence compared with
higher expression.
Table 2 Cox proportional Hazards models for estimating the effect on time to recurrence
Univariate Multivariate
HR (95% CI) c12 P value HR (95% CI) c12 P value
All patients
CCND1, amplified vs. nonamplified 2.04 (1.37 to 3.03) 10.51 < 0.001 1.61 (1.08 to 2.41) 4.86 0.030
Cyclin D1 cytoplasmic intensity, high vs. remainder 0.71 (0.51 to 0.98) 4.43 0.039 0.78 (0.56 to 1.09) 2.15 0.143
Cyclin D1 nuclear intensity, high vs. remainder 0.91 (0.64 to 1.28) 0.30 0.588 0.85 (0.59 to 1.21) 0.84 0.360
Cyclin D1 nuclear fraction, 1 to 100% vs. < 1% 0.58 (0.38 to 0.90) 5.28 0.014 0.60 (0.39 to 0.92) 4.75 0.030
Nonamplified patients
Cyclin D1 cytoplasmic intensity, high vs. remainder 0.57 (0.39 to 0.82) 9.57 0.003 0.64 (0.44 to 0.95) 5.21 0.022
Cyclin D1 nuclear intensity, high vs. remainder 0.88 (0.60 to 1.32) 0.38 0.545 0.84 (0.55 to 1.26) 0.76 0.382
Cyclin D1 nuclear fraction, 1 to 100% vs. < 1% 0.52 (0.34 to 0.81) 7.29 0.004 0.54 (0.35 to 0.85) 6.36 0.012
The c1
2 value is based on the likelihood ratio test with the associated P values. Multivariate analyses were adjusted for tumour grade, tumour size, nodal status
and Ki67. CI, confidence interval; HR, hazard ratio.
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with the other subgroups. The subgroups of low cyclin D1
include quite low patient numbers and hence the results
should be interpreted with caution, but these results sug-
gest that the expression of cyclin D1 affects disease out-
come independently of proliferation status.
Discussion
Amplification of the CCND1 gene has been associated
with a poor patient outcome in previous studies [19,26],
whilst controversy regarding overexpression of cyclin D1
protein in relation to patient survival still exists. Cyclin D1
has been reported to be a prognostic marker in invasive
breast cancer and has been associated with both a less
aggressive ER-positive phenotype [20,22] and also with an
adverse clinical outcome [18]. These conflicting findings
can potentially be explained by the low patient numbers
analysed and/or methodological discrepancies. To clarify
the importance of cyclin D1 in breast cancer we therefore
analysed the expression of cyclin D1 in different subcellu-
lar localisations, using a previously validated antibody [36],
as well as the gene amplification status by the well-estab-
lished CISH technique in a large, well-characterised ran-
domised patient cohort including more than 1,000
patients with ER-positive breast cancers. Our data support
studies indicating that low cyclin D1 protein expression as
well as CCND1 amplification are linked to tumour aggres-
siveness and increased risk of disease recurrence in ER-
positive postmenopausal breast cancer [23,26]. Similar
findings have been observed for HER2, where both high
expression linked to amplification and low expression are
linked to poor outcome [43].
Amplification of CCND1 was observed in 8.7% of the
tumours, which is slightly lower than the frequency of 10
to 15% generally reported, even though some groups
have demonstrated a lower percentage of CCND1-ampli-
fied tumours [15,44,45]. The slightly lower fraction of
CCND1-amplified cases may be due to all patients being
ER-positive or due to methodological differences and dif-
ferent cutoff points for defining amplification between
studies. In addition, the use of TMAs has certain
Figure 3 Predicted risk of recurrence over time based on cytoplasmic intensity and nuclear fraction of cyclin D1, comparing two
subgroups. (a) In all patients, no significant difference in recurrence risk was observed between low and high cytoplasmic expression. (b)
Patients showing a nuclear fraction of less than 1% positive cyclin D1 nuclei had an increased risk of recurrence compared with a fraction of 1 to
100%, in all patients. (c) In patients exhibiting nonamplified tumours, high cytoplasmic expression was associated with a reduced risk of
recurrence. (d) A fraction of cyclin D1-positive nuclei lower than 1% was associated with a higher recurrence risk also in patients showing
nonamplified tumours.
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Figure 4 Forest plot showing the effect of CCND1 amplification, cytoplasmic and nuclear cyclin D1 expression. (a) Amplified against
nonamplified breast cancers in the subgroups of treatment, nodal status and Ki67. (b) High cytoplasmic intensity against low or intermediate
intensity. (c) Nuclear fraction of 1 to 100% against < 1% positive nuclei. Reference population for all subgroups was nonamplified patients
(except for amplification status). HR, hazard ratio; neg, negative; pos, positive.
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limitations; however, this technique is indispensable
when analysing large patient materials and is today a
well-accepted approach for large-scale tumour sample
analysis. In agreement with previous studies, gene ampli-
fication of CCND1 was associated with an overall adverse
clinical outcome. The observed positive correlation
between nuclear cyclin D1 expression and tumour grade
and proliferation suggests a link between cyclin D1 and
aggressive disease. In contrast, both higher nuclear
expression and high cytoplasmic expression of cyclin D1
was instead associated with a decreased recurrence risk.
Despite a positive association between cyclin D1 protein
and CCND1 amplification status, both low nuclear frac-
tion of cyclin D1 and CCND1 amplification were linked
to earlier disease recurrence independently of other clini-
copathological parameters - hence both factors serve as
prognostic markers in endocrine-treated, ER-positive
postmenopausal breast cancer. In patients not displaying
CCND1 amplification, cytoplasmic expression of cyclin
D1 was also an independent marker for longer TTR, indi-
cating that the true prognostic value of cyclin D1 protein
expression may be obscured by the CCND1-amplified
cases: the clinicopathological significance of cyclin D1
expression might thus be best considered separately for
amplified and nonamplified cases.
Apart from the role as a prognostic marker, cyclin D1
has been proposed as a predictive factor for tamoxifen
response, as illustrated by poor clinical outcome in
patients with ER-positive tumours with high cyclin D1
expression treated with tamoxifen [46]. These findings
together with numerous experimental reports [33-35]
support that cyclin D1 overexpression might abrogate the
response to tamoxifen, as previously reported by our
group and others [21,46]. Our earlier discoveries have
nevertheless been made in cohorts where patients were
randomly assigned to receive either no adjuvant treat-
ment or to receive tamoxifen [21,36]. In the present
study we compared the two endocrine therapies anastro-
zole and tamoxifen in relation to disease recurrence and
cyclin D1 status, but there were no untreated control
patients. There was no significant difference in treatment
response between these two adjuvant therapies by strati-
fication for cyclin D1 status, indicating that cyclin D1 is
not a predictive marker for differences in response to
anastrozole versus tamoxifen. No conclusions can be
drawn, however, regarding cyclin D1 as a marker for gen-
eral endocrine treatment resistance, since no untreated
patients were available for analysis within the Trans-
ATAC study. Moreover, differences in tamoxifen
response in relation to cyclin D1 in postmenopausal ver-
sus premenopausal breast cancer might exist. Our pre-
vious study reporting a potential unfavourable effect of
tamoxifen included premenopausal patients exclusively,
whereas this study focused exclusively on postmenopau-
sal breast cancer cases and has shown no detrimental
effect since the results for the two endocrine therapies
were similar.
The relationship between cyclin D1, proliferation and
prognosis is quite complex, with a positive correlation
between cyclin D1 and Ki67 - Ki67 is associated with
shorter TTR, while cyclin D1 is associated with longer
TTR. Patients showing low expression of Ki67 had a
longer TTR with the highest levels of cyclin D1 expres-
sion, whereas patients exhibiting higher levels of Ki67
had the shortest TTR with the lowest levels of cyclin D1
expression. Multivariate analysis identified the fraction
cyclin D1-positive nuclei as a predictor of outcome inde-
pendently of other clinicopathological parameters such as
Ki67. These results suggest that, irrespective of prolifera-
tion status, intermediate to high expression of cyclin D1
Figure 5 Recurrence risk over time based on the expression of Ki67 and cyclin D1. (a) Expression of Ki67 increased with increasing
percentage of cyclin D1-positive nuclei in the breast tumours. (b) Kaplan-Meier plot showing that the combination of high Ki67 and low cyclin
D1 expression was associated with high risk of recurrence (green). Patients exhibiting a high fraction of cyclin D1-positive tumour cell nuclei in
concurrence with low Ki67 expression showed the lowest risk of recurrence (red).
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results in a prolonged TTR in ER-positive, postmenopau-
sal breast cancer patients. Similar results were observed
in our previous study of randomised material from pre-
menopausal breast cancer patients [47]. The relationship
between cyclin D1, proliferation and prognosis hence
seems to be complex, and this could in part be explained
by potential additional functions for cyclin D1 unrelated
to proliferation control, as well as co-amplification and
co-deletion of specific genes on chromosome 11q13, the
locus harbouring CCND1.
Conclusions
This study confirms that the cyclin D1 status provides
independent prognostic information regarding ER-posi-
tive, postmenopausal breast cancers, supporting its emer-
ging role as a biomarker that might be useful in the clinic.
Our results demonstrate that high expression of cyclin D1
was associated with a reduced risk of recurrences, whereas
amplification of the CCND1 gene was linked to an aggres-
sive disease. Finally, no difference in response to anastro-
zole compared with tamoxifen was observed according to
expression of cyclin D1 gene amplification or protein
expression.
Additional material
Additional file 1: Supplementary Table 1showing the distribution of
cyclin D1 staining categories.
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